Search
Halcinonide
go.drugbank.com/drugs/DB06786ApprovedWithdrawnResearch suggests that clobetasol propionate demonstrates superior pharmacologic efficacy in the treatment of psoriasis when compared to halcinonide. … Halcinonide is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, and is distributed as a cream and ointment.
Categories: Corticosteroid Hormone Receptor AgonistsInternational brands: Ha Le TeCrinecerfont
go.drugbank.com/drugs/DB18518ApprovedInvestigational[A264818] Crinecerfont is a selective antagonist of corticotropin-releasing factor (CRF) type 1 receptor that works to reduce excessive ACTH secretion from the pituitary. … [A264818] The majority of the poor health outcomes in patients with CAH result from the inability to precisely titrate glucocorticoid dosages to both adequately replace the deficiency and sufficiently
Categories: Corticotropin-releasing Factor Type 1 Receptor AntagonistFruquintinib
go.drugbank.com/drugs/DB11679ApprovedInvestigationalTumor angiogenesis is one of the most critical biological processes for increasing oxygen and nutrient supply to cancer cells, and the VEGF/VEGFR pathway is one of the most critical pathways for this phenomenon … The first approach can be exemplified by [bevacizumab], a VEGF-A trap antibody.
Categories: Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitorsRuxolitinib
go.drugbank.com/drugs/DB08877ApprovedInvestigationalBy inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. … [A229938] Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012.
Levamlodipine
go.drugbank.com/drugs/DB09237ApprovedInvestigational[L1484] The names S-amlodipine and levamlodipine may be used interchangeably as both substances are the same, however. … [L10833] Levamlodipine belongs to the dihydropyridine group of calcium channel blockers.[L10833] This medication was first marketed in Russia and India before being granted FDA approval.
Piperazine
go.drugbank.com/drugs/DB00592ApprovedVet approvedWithdrawnPiperazine compounds mediate their anthelmintic action by generally paralyzing parasites, allowing the host body to easily remove or expel the invading organism. … Upon entry into the systemic circulation, the drug is partly oxidized and partly eliminated as an unchanged compound.
Iopromide
go.drugbank.com/drugs/DB09156Approved[A260751] Although the mechanism is unclear, women and outpatients tend to have a higher incidence of adverse events compared to other population groups. … It functions as a contrast agent by opacifying blood vessels in the flow path of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs
Imatinib
go.drugbank.com/drugs/DB00619ApprovedInvestigationalThe discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. … [L42220] Imatinib was approved on February 1st ,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751]
Elotuzumab
go.drugbank.com/drugs/DB06317ApprovedInvestigationalone to three prior therapies. … Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. Food and Drug Administration.
Erdosteine
go.drugbank.com/drugs/DB05057ApprovedInvestigationalErdosteine has been shown to be safe and well tolerated in clinical trials. … Co-administration of erdosteine and amoxicillin in patients with acute infective exacerbation of chronic bronchitis resulted in higher concentrations of the antibiotic in the sputum, leading to earlier